PLX065 reduces liver fat content, prevents worsening of fibrosis in NASH

WASHINGTON — PXL065, a novel PPAR gamma-sparing chemical entity of pioglitazone, reduced liver fat content with no dose-dependent effect on weight gain in patients with nonalcoholic steatohepatitis, according to late-breaking data.“Pioglitazone has been extensively studied for many years. … There have been at least six biopsy trials of varying durations, varying numbers of patients included in the trial, each showing histopathological and biochemical benefit,” Stephen A. Harrison, MD, FAASLD, medical director for Pinnacle Clinical Research and president of Summit ClinicalRead More

Generated by Feedzy